Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (HIMS)
NYSE:HIMS
HIMS Stock Chart & Stats
$19.33
-$0.61(-2.20%)
At close: 4:00 PM EST
$19.33
-$0.61(-2.20%)
Day’s Range― - ―
52-Week Range$16.35 - $72.98
Previous CloseN/A
Volume4.28M
Average Volume (3M)18.62M
Market Cap
$5.24B
Enterprise Value$5.01B
Total Cash (Recent Filing)$629.74M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)35.7
Beta2.68
Next Earnings
Feb 23, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding219,270,890
10 Day Avg. Volume27,254,607
30 Day Avg. Volume18,618,832
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)10.95
Price to Sales (P/S)3.54
P/FCF Ratio26.33
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.27
Enterprise Value/Gross Profit3.02
Enterprise Value/Ebitda31.73
Forecast
1Y Price Target
$32.95Price Target Upside70.46% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)0.58
Revenue Forecast (FY)$2.78B
Bulls Say, Bears Say
Bulls Say
Compounding ComplianceCompany states active pharmaceutical ingredients for compounded treatments are sourced from FDA‑registered facilities and comply with federal and state compounding standards, which could strengthen legal defenses and allow some personalized compounding to continue if regulators limit only mass marketing.
Consumer Demand And Marketing TractionRising web traffic on the consumer site combined with a prior successful marketing push indicates persistent patient interest that could sustain demand for permitted compounded offerings.
Operational InfrastructureLarge integrated pharmacy, laboratory and research capabilities provide scalable compounding operations that could be redeployed to support permitted personalized therapies and mitigate disruption from narrower regulatory actions.
Bears Say
Patent Litigation RiskNovo Nordisk's patent infringement claim seeking damages and an injunction exposes the company to potentially costly litigation outcomes that could restrict product offerings and increase financial liability.
Product Removal And Capacity UncertaintyThe company halted its oral compounded semaglutide product amid regulatory scrutiny, creating the risk that a key growth driver is lost and planned manufacturing capacity may be difficult to repurpose if demand for this product does not materialize.
Regulatory Enforcement And Ingredient AccessFDA signals to restrict GLP‑1 active ingredients for use in non‑approved compounded drugs and specifically named the company, raising the possibility that access to core ingredients could be limited and curtail compounding revenue.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $16.35 and its highest was $72.98 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $5.24B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Feb 23, 2026 which is in 12 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Nov 03, 2025. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.094 by -$0.034.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is 0.04.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 219,270,890 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of $0.06 in its last earnings report, missing expectations of $0.094. Following the earnings report the stock price went down -3.604%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.95 (70.46% Upside)
$32.95 (70.46% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $512.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bearish
Bullish news 13%
Bearish news 87%
Bearish news 87%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.57%
12-Months-Change
Fundamentals
Return on Equity
26.21%
Trailing 12-Months
Asset Growth
270.82%
Trailing 12-Months
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
HIMS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a strong performance with significant revenue growth, strategic partnerships, and international expansion. However, there are challenges in gross margins and increased G&A costs. The company's strategy and future outlook remain optimistic.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$32.95
▲(70.46% Upside)
Technical Analysis
Ownership Overview
5.10% Insiders
23.67% Mutual Funds
3.02% Other Institutional Investors
46.91% Public Companies and Individual Investors